DelMar Pharma OK'd to Start Trial of Lead Drug in Ovarian Cancer Patients

DelMar Pharma was approved to start a Phase I trial of its lead molecule, VAL-083, in patients with ovarian cancer. The US trial is the second indication for VAl-083, which is already in US and China trials for refractory brain cancer. Several years ago, when DelMar started looking for a supplier of VAL-083, it discovered that Guangxi Wuzhou Pharma offered the drug in China for leukemia and lung cancer. They struck a partnership under which Wuzhou will provide global supplies of the drug to DelMar, while the two companies would partner on new indications of the drug in China . DelMar owns ex-China rights. DelMar is headquartered in Vancouver and has a clinical operations office in Menlo Park . More details.... Stock Symbol: (NSDQ: DMPI) Share this with colleagues: // //